Virus reactivation in pigs latently infected with a thymidine kinase negative vaccine strain of pseudorabies virus.
Attenuated, gene-deletion mutants of pseudorabies virus (PRV) were tested for their ability to establish a reactivatable latent infection in pigs. The viruses (designated A, B, and C) were from each of three vaccines commercially available in the United States. Viruses A and C were similar in that they had genetically engineered gene deletions for thymidine kinase (TK) and glycoprotein X (gX); however, they had been prepared from genetically different parental strains. Virus B was TK positive, but had a naturally occurring gene deletion for glycoprotein I (gI). Four pigs were exposed oronasally to each of the viruses, and 10 weeks later they were treated with dexamethasone in an attempt to induce virus reactivation. All of the viruses replicated after initial exposure as evidenced by virus isolation from nasal swabs and the pigs' immune responses. Virus reactivation was subsequently induced by dexamethasone treatment in two of four pigs exposed to virus A. Notably, both pigs remained free of serum antibody for gX. Restriction endonuclease analysis and tests for TK activity and the presence of gX indicated that reactivated virus was similar, if not identical, to virus A used to establish latent infection. Virus shedding after dexamethasone treatment was not identified for either of the other pigs exposed to virus A nor for any of the pigs exposed to viruses B or C. The results indicated that attenuated, TK-negative PRV can establish a reactivatable, latent infection in pigs.
Mengeling
W L
WL
USDA, National Animal Disease Center, Ames, Iowa.
D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002478:Cells, Cultured; D003907:Dexamethasone / Q000494:pharmacology; D011558:Herpesvirus 1, Suid / Q000201:enzymology / Q000254:growth & development / Q000472:pathogenicity*; D011557:Pseudorabies / Q000209:etiology* / Q000382:microbiology; D011897:Random Allocation; D013552:Swine; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins / Q000096:biosynthesis; D010948:Viral Plaque Assay; D014765:Viral Vaccines / Q000009:adverse effects*; D014775:Virus Activation
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C042966:pseudorabies virus glycoproteins; D003907:Dexamethasone